Clinical Report: OPTILATER Study on Long-Term Survival Among Cancer Survivors in Germany

Overview

The OPTILATER project aims to evaluate the long-term survival and care conditions of cancer survivors in Germany, focusing on the late effects of cancer treatment. This cross-sectional study highlights the need for improved follow-up care, especially for survivors with migration backgrounds.

Background

The increasing number of cancer survivors in Germany necessitates a better understanding of their long-term care needs, particularly regarding late effects from treatments. Many survivors lack adequate information about potential risks and follow-up care, which can lead to increased morbidity and psychological distress. Addressing these gaps is critical for enhancing the quality of life among cancer survivors.

Data Highlights

No numerical data available in the provided source material.

Key Findings

• The number of cancer survivors in Germany reached 4.65 million in 2017, with two-thirds being long-term survivors.
• Late effects from cancer treatments can lead to significant health impairments and psychological distress.
• Survivors with migration backgrounds may face disparities in accessing post-treatment care.
• The OPTILATER project aims to systematically evaluate the needs of cancer survivors and improve survivorship care.
• Data collection focuses on health-related quality of life, psychological well-being, and unmet needs for digital health interventions.

Clinical Implications

Healthcare providers should be aware of the long-term effects of cancer treatments and ensure that survivors receive appropriate follow-up care. Special attention is needed for survivors from minority and underrepresented groups to address potential disparities in care access and quality.

Conclusion

The OPTILATER project represents a significant step toward understanding and improving the long-term care of cancer survivors in Germany. By identifying unmet needs, the study aims to enhance the overall quality of life for this growing population.

References

1. Krebsdaten.de, Krebs in Deutschland, 2023 -- Cancer in Germany 2023
2. Mayo Clinic, Survivorship, Version 2.2025 Featured Updates to the NCCN Guidelines®, 2025
3. Journal of Neuro-Oncology — Comparison of Physician-led and Questionnaire-based Psychosocial Assessments in Adults with High-Grade Glioma: Results from a Cluster-Randomized Controlled Trial (GLIOPT)
4. BJS (British Journal of Surgery) — Validation of the LASORS Tool for Assessing Long-Term Symptoms Following Oesophageal Resection: A Multicentre Cohort Study
5. Blood Cancer Journal — A German Analysis of Socioeconomic Factors Affecting Diffuse Large B-Cell Lymphoma Outcomes
6. Assessment of a German Version of the CARE Questionnaire and Its Use as an Electronic Patient-Reported Outcome Measure for Evaluating Postoperative Recovery Following Major Urological Surgery
7. Krebs - Krebs in Deutschland - Krebs in Deutschland für 2019/2020
8. Survivorship, Version 2.2025 Featured Updates to the NCCN Guidelines® - Mayo Clinic
9. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma - PMC